CFB
SAGE

Cullen/Frost Bankers’s Sage Therapeutics SAGE Stock Holding History

Cullen/Frost Bankers’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-165
Closed -$5K – 1136
2020
Q1 		$5K Sell
165
-28
-15% -$1.62K ﹤0.01% 797
2019
Q4 		$14K Sell
193
-155
-45% -$19.1K ﹤0.01% 859
2019
Q3 		$49K Sell
348
-52
-13% -$8.7K ﹤0.01% 565
2019
Q2 		$73K Sell
400
-200
-33% -$34.1K ﹤0.01% 510
2019
Q1 		$95K Buy
+600
New +$86.9K ﹤0.01% 478

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Cullen/Frost Bankers's SAGE Position: Q2 2020 in Review

Cullen/Frost Bankers sold out of Sage Therapeutics (SAGE) in Q2 2020, closing a stake of 165 shares — an estimated $5K sold.

Cullen/Frost Bankers first reported a position in SAGE in Q1 2019 and held it in 5 quarters. The position peaked at $95K in Q1 2019. 217 funds tracked by Wall St. Rank hold SAGE as of Q2 2020.

  • Cullen/Frost Bankers reported no remaining Sage Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Cullen/Frost Bankers sold 165 Sage Therapeutics shares in Q2 2020, an estimated $5K.
  • Cullen/Frost Bankers first reported a position in Sage Therapeutics in Q1 2019 and held it in 5 quarters.
  • Cullen/Frost Bankers's Sage Therapeutics position peaked at $95K in Q1 2019.
  • 217 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2020.

Based on Cullen/Frost Bankers's 13F filing for Q2 2020, filed 5 Aug 2020.